Stock Chart

RIGL

$36.01 +3.30%
Score: 51.4 HOLD
1Y Target $35.51 -1.4%
i
1Y Price Target

This target is derived from long-term trendline analysis and projected growth.

Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.

Target may adjust dynamically as the stock trend reverses or accelerates.
LEAPs: SELL $48
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $48
Premium: $9.09
Expiry: Jun 18, 2026
Target: $47
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $25.65 - $39.32 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.31
Vol: 0.50x (vs SPY: 0.5x | vs QQQ: 0.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About RIGL - Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Key Statistics

Market Cap $633M
P/E Ratio 5.63

This RIGL stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track RIGL's price movements with trendlines, gamma walls, and key support/resistance levels.